James W. Brush, M.D.


Jamie is a Partner on the Frazier Life Sciences team and co-leads Frazier’s public equity investment strategy.

Jamie joined Frazier Healthcare Partners in 2016 and invests in private and public development stage biotechnology companies. He has been involved in all Frazier Life Sciences public investments since joining the firm including ARMO (acquired by Eli Lilly), Ignyta (acquired by Roche), Adverum Biotechnologies (NASDAQ: ADVM), Krystal Biotech (NASDAQ: KRYS), Sutro Biopharma (NASDAQ: STRO), Syndax Pharmaceuticals (NASDAQ: SNDX), Translate Bio (NASDAQ: TBIO), and Trillium Therapeutics (NASDAQ: TRIL). In addition, Jamie represents Frazier on the board of Amunix Pharmaceuticals and Dascena.

Prior to joining Frazier, Jamie was a management consultant with the Boston Consulting Group, where he was a core member of the Healthcare Practice. In this capacity, he led projects involving Biotechnology mergers and acquisitions, R&D, manufacturing and business development strategy.

Jamie received his M.D. from the University of Southern California, where he was inducted into the Alpha Omega Alpha honors society, and his B.A. from Middlebury College. He completed his post-graduate training in Internal Medicine at Beth Israel Deaconess Medical Center in Boston.

Menlo Park

Middlebury College (B.A.)
University of Southern California (M.D.)

Year Joined